Updated:
Life Biosciences Inc.
Life Biosciences is the only company with FDA clearance to test epigenetic restoration in humans. It raised $80M Series D in 2026.
Life Biosciences Inc.
Life Biosciences was founded to commercialize epigenetic restoration technology, a method that rewinds cellular age by resetting epigenetic marks. The company is headquartered in Boston and has not publicly disclosed its founding year or founders. Its wealth origin or corporate parentage remains private. The company's pipeline targets age-related diseases, with an initial focus on optic neuropathies via its candidate ER-100. Beyond the eye, preclinical programs address liver and other degenerative conditions. Life Biosciences reported an FDA IND clearance for ER-100 in January 2026 and a research collaboration with SingHealth Duke-NUS REMEDIS in July 2025. Its platform is covered by intellectual property for therapeutic epigenetic restoration. Life Biosciences has raised at least $80 million in a Series D round announced April 2026 (per firm newsroom, April 2026). The company's team size is undisclosed, and no additional offices beyond Boston are listed. Adjacent structures are not publicly identified. A key differentiator is regulatory: Life Biosciences is the sole company with FDA clearance to advance epigenetic restoration into human trials. This first-mover position in the regulatory pathway for cellular rejuvenation therapies creates a distinct barrier to entry for competitors.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
75 Park Plaza Level Three, Boston, MA 02116, United States
Sector focus
Frequently asked questions
What is Life Biosciences' core technology?
Life Biosciences develops epigenetic restoration, a process that resets epigenetic marks to revert cells to a younger, healthier state. The company claims to be the only one with intellectual property covering the therapeutic use of this technology (per firm website). Its platform targets age-related diseases, with initial focus on optic neuropathies.
Has Life Biosciences received FDA approval for any treatment?
The firm has FDA clearance for an Investigational New Drug (IND) application for ER-100, its candidate for optic neuropathies (announced January 2026). This is the first FDA clearance for a therapeutic epigenetic restoration approach.
How is Life Biosciences funded?
Life Biosciences raised an $80 million Series D in April 2026 (per firm press release, April 2026). The company does not disclose its full financing history or valuation. Ownership structure is not public.
Who are Life Biosciences' executives or board members?
Life Biosciences' leadership team and board are not listed on the public website. The company appointed David Guyer, M.D. to the board in November 2025 (per firm newsroom, November 2025), but no other named principals are disclosed.
What diseases does Life Biosciences target?
The company's initial clinical program targets optic neuropathies. Preclinical work includes liver disease and ocular diseases. The broader platform aims to address multiple age-related illnesses, though specific pipeline details beyond eye and liver programs are not public.
Does Life Biosciences have any research collaborations?
In July 2025, Life Biosciences announced a research collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to expand its pipeline of cellular rejuvenation therapies (per firm newsroom, July 2025). No other collaborations are disclosed.
How does Life Biosciences differentiate from other aging biotech companies?
Life Biosciences is the only company with FDA clearance to advance epigenetic restoration into human clinical studies (per firm website). It also holds intellectual property covering the therapeutic use of this specific technology, creating a regulatory and IP moat.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: